Lv31
240 积分 2024-01-04 加入
[Epidemiology of prostate cancer in China: an overview and clinical implication]
10小时前
已完结
Targeted therapy in prostate cancer: beyond PSMA
4个月前
已关闭
177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
6个月前
已完结
Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study
6个月前
已完结
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received177Lu-PSMA-617: Importance of18F-FDG–Avid Discordant Findings
6个月前
已关闭
Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre
7个月前
已完结
PO-1473 PSMA PET imaging of non-acinar histological variants of prostate cancer
7个月前
已完结
Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy
8个月前
已完结
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
1年前
已完结
First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China
1年前
已完结
皖公网安备34019202002308
